Partial
Partially Aligned
Patient Risk:
Low
Summary
Partial alignment limited to a general triglyceride-reduction/adjunct indication supported by Section 1. Most other claims (notably all “Vascepa assistance” program details, eligibility requirements, income thresholds, and sponsoring entities) are absent from the provided FDA label section and therefore unsupported.
Category Scores
Accurate Statements
Vascepa is used to lower triglyceride levels in the blood.
Section 1 INDICATIONS AND USAGE: adjunct to diet to reduce TG levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia.
Vascepa is used to reduce risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adults with elevated triglyceride levels (≥150 mg/dL) who have established cardiovascular disease or diabetes mellitus with additional risk factors.
Section 1 INDICATIONS AND USAGE (as described in the label text).
Unsupported Statements
Vascepa (icosapent ethyl) is a prescription medication.
Absent from the provided label section (Section 1 INDICATIONS AND USAGE).
Vascepa is often prescribed for patients with high triglyceride levels.
Label supports an indication for adult patients with elevated TG levels meeting specific criteria, but the claim’s 'often prescribed' wording is not supported by the provided label.
Vascepa is often prescribed for patients with a history of cardiovascular disease.
Label supports use in adults with elevated TG levels with established cardiovascular disease, but the claim’s 'often prescribed' wording is not supported by the provided label.
Vascepa assistance refers to programs and resources that help patients cover the cost of Vascepa.
Cost-assistance program information is absent from the provided label section.
The described Vascepa assistance may include patient assistance programs (PAPs), copay cards, and non-profit organizations that provide financial assistance to patients in need.
Absent from the provided label section.
To be eligible for Vascepa assistance, patients must have a valid prescription from a healthcare provider.
Absent from the provided label section.
To be eligible for Vascepa assistance, patients may need to meet income requirements.
Absent from the provided label section.
The Vascepa PAP requires patients to have an annual income of $100,000 or less.
Absent from the provided label section.
To be eligible for Vascepa assistance, patients may need insurance coverage that includes Vascepa.
Absent from the provided label section.
Some programs may offer assistance to patients without insurance.
Absent from the provided label section.
To be eligible for Vascepa assistance, patients must meet medical requirements such as having high triglyceride levels or a history of cardiovascular disease.
Absent from the provided label section as eligibility criteria for assistance programs.
The Vascepa PAP is a patient assistance program offered by Amarin Pharmaceuticals.
Absent from the provided label section.
The Vascepa copay card is a program offered by Amarin Pharmaceuticals.
Absent from the provided label section.
The Vascepa Patient Assistance Program is described as a non-profit organization that provides financial assistance to patients who cannot afford Vascepa.
Absent from the provided label section.
Repetition of assistance program eligibility requirements (valid prescription, income ≤$100,000, insurance includes Vascepa, and condition-based criteria such as high triglycerides or cardiovascular disease) for PAP/copy card/PAP.
All such assistance eligibility specifics are absent from the provided label section.
Contradictions
Important Omissions
If evaluating prescribing appropriateness, the label-required eligibility thresholds and population modifiers (e.g., TG ≥150 mg/dL; adjunct to maximally tolerated statin therapy; severe hypertriglyceridemia TG ≥500 mg/dL; established cardiovascular disease vs diabetes with additional risk factors) are not fully reflected in the response’s broader 'often prescribed' framing.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only label-supported content pertains to indication framing; however, many cost-assistance and eligibility details are absent from the provided label section, which could mislead but does not directly change medication safety information within the evaluated excerpt.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Multiple claims about 'Vascepa assistance' (program types, sponsor, and eligibility requirements including $100,000 income threshold and insurance criteria) are not present in the provided FDA label section and are therefore unsupported.
Suggested Improvement
Restrict claims to what is explicitly supported by the provided label text (Section 1 indications and the specified TG thresholds/populations). Remove or clearly segregate any cost-assistance program details as non-label information not derived from prescribing information.